ID D5G334_CANFA Unreviewed; 170 AA. AC D5G334; DT 15-JUN-2010, integrated into UniProtKB/TrEMBL. DT 15-JUN-2010, sequence version 1. DT 24-JUN-2015, entry version 27. DE SubName: Full=Apolipoprotein E4 {ECO:0000313|EMBL:ADB55604.1}; DE Flags: Fragment; OS Canis familiaris (Dog) (Canis lupus familiaris). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Laurasiatheria; Carnivora; Caniformia; Canidae; OC Canis. OX NCBI_TaxID=9615 {ECO:0000313|EMBL:ADB55604.1}; RN [1] {ECO:0000313|EMBL:ADB55604.1} RP NUCLEOTIDE SEQUENCE. RC STRAIN=Tu001 {ECO:0000313|EMBL:ADB55604.1}; RA Leelamanit W., Jittikoon J.; RT "Apolipoprotein E4 gene is conserved through out mammal species."; RL Submitted (APR-2009) to the EMBL/GenBank/DDBJ databases. CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000256|SAAS:SAAS00143437}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; FJ948095; ADB55604.1; -; Genomic_DNA. DR STRING; 9615.ENSCAFP00000006888; -. DR Reactome; REACT_274288; HDL-mediated lipid transport. DR Reactome; REACT_335920; Retinoid metabolism and transport. DR Reactome; REACT_337783; Chylomicron-mediated lipid transport. DR Reactome; REACT_345639; Scavenging by Class A Receptors. DR GO; GO:0072562; C:blood microparticle; IEA:Ensembl. DR GO; GO:0042627; C:chylomicron; IEA:Ensembl. DR GO; GO:0070062; C:extracellular exosome; IEA:Ensembl. DR GO; GO:0031012; C:extracellular matrix; IEA:Ensembl. DR GO; GO:0034364; C:high-density lipoprotein particle; IEA:Ensembl. DR GO; GO:0034363; C:intermediate-density lipoprotein particle; IEA:Ensembl. DR GO; GO:0034362; C:low-density lipoprotein particle; IEA:Ensembl. DR GO; GO:0016020; C:membrane; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; IEA:Ensembl. DR GO; GO:0034361; C:very-low-density lipoprotein particle; IEA:Ensembl. DR GO; GO:0016209; F:antioxidant activity; IEA:Ensembl. DR GO; GO:0001540; F:beta-amyloid binding; IEA:Ensembl. DR GO; GO:0017127; F:cholesterol transporter activity; IEA:Ensembl. DR GO; GO:0008201; F:heparin binding; IEA:Ensembl. DR GO; GO:0071813; F:lipoprotein particle binding; IEA:Ensembl. DR GO; GO:0046911; F:metal chelating activity; IEA:Ensembl. DR GO; GO:0060228; F:phosphatidylcholine-sterol O-acyltransferase activator activity; IEA:Ensembl. DR GO; GO:0005543; F:phospholipid binding; IEA:Ensembl. DR GO; GO:0097113; P:alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor clustering; IEA:Ensembl. DR GO; GO:0048844; P:artery morphogenesis; IEA:Ensembl. DR GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl. DR GO; GO:0019934; P:cGMP-mediated signaling; IEA:Ensembl. DR GO; GO:0006707; P:cholesterol catabolic process; IEA:Ensembl. DR GO; GO:0033344; P:cholesterol efflux; IEA:Ensembl. DR GO; GO:0042632; P:cholesterol homeostasis; IEA:Ensembl. DR GO; GO:0034382; P:chylomicron remnant clearance; IEA:Ensembl. DR GO; GO:0055089; P:fatty acid homeostasis; IEA:Ensembl. DR GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IEA:Ensembl. DR GO; GO:0034380; P:high-density lipoprotein particle assembly; IEA:Ensembl. DR GO; GO:0034384; P:high-density lipoprotein particle clearance; IEA:Ensembl. DR GO; GO:0034375; P:high-density lipoprotein particle remodeling; IEA:Ensembl. DR GO; GO:0042158; P:lipoprotein biosynthetic process; IEA:Ensembl. DR GO; GO:0042159; P:lipoprotein catabolic process; IEA:Ensembl. DR GO; GO:0015909; P:long-chain fatty acid transport; IEA:Ensembl. DR GO; GO:0034374; P:low-density lipoprotein particle remodeling; IEA:Ensembl. DR GO; GO:0051651; P:maintenance of location in cell; IEA:Ensembl. DR GO; GO:0097114; P:N-methyl-D-aspartate receptor clustering; IEA:Ensembl. DR GO; GO:1902430; P:negative regulation of beta-amyloid formation; IEA:Ensembl. DR GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IEA:Ensembl. DR GO; GO:0045541; P:negative regulation of cholesterol biosynthetic process; IEA:Ensembl. DR GO; GO:0090370; P:negative regulation of cholesterol efflux; IEA:Ensembl. DR GO; GO:0061000; P:negative regulation of dendritic spine development; IEA:Ensembl. DR GO; GO:1902951; P:negative regulation of dendritic spine maintenance; IEA:Ensembl. DR GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IEA:Ensembl. DR GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl. DR GO; GO:1903001; P:negative regulation of lipid transport across blood brain barrier; IEA:Ensembl. DR GO; GO:0043407; P:negative regulation of MAP kinase activity; IEA:Ensembl. DR GO; GO:1901215; P:negative regulation of neuron death; IEA:Ensembl. DR GO; GO:1902999; P:negative regulation of phospholipid efflux; IEA:Ensembl. DR GO; GO:0010544; P:negative regulation of platelet activation; IEA:Ensembl. DR GO; GO:1901627; P:negative regulation of postsynaptic membrane organization; IEA:Ensembl. DR GO; GO:1901630; P:negative regulation of presynaptic membrane organization; IEA:Ensembl. DR GO; GO:0007263; P:nitric oxide mediated signal transduction; IEA:Ensembl. DR GO; GO:0033700; P:phospholipid efflux; IEA:Ensembl. DR GO; GO:1902004; P:positive regulation of beta-amyloid formation; IEA:Ensembl. DR GO; GO:0030828; P:positive regulation of cGMP biosynthetic process; IEA:Ensembl. DR GO; GO:0010875; P:positive regulation of cholesterol efflux; IEA:Ensembl. DR GO; GO:0010873; P:positive regulation of cholesterol esterification; IEA:Ensembl. DR GO; GO:0060999; P:positive regulation of dendritic spine development; IEA:Ensembl. DR GO; GO:1902952; P:positive regulation of dendritic spine maintenance; IEA:Ensembl. DR GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IEA:Ensembl. DR GO; GO:1903002; P:positive regulation of lipid transport across blood brain barrier; IEA:Ensembl. DR GO; GO:0032805; P:positive regulation of low-density lipoprotein particle receptor catabolic process; IEA:Ensembl. DR GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; IEA:Ensembl. DR GO; GO:1902998; P:positive regulation of neurofibrillary tangle assembly; IEA:Ensembl. DR GO; GO:1901216; P:positive regulation of neuron death; IEA:Ensembl. DR GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IEA:Ensembl. DR GO; GO:1902995; P:positive regulation of phospholipid efflux; IEA:Ensembl. DR GO; GO:1901628; P:positive regulation of postsynaptic membrane organization; IEA:Ensembl. DR GO; GO:1901631; P:positive regulation of presynaptic membrane organization; IEA:Ensembl. DR GO; GO:0017038; P:protein import; IEA:Ensembl. DR GO; GO:0006898; P:receptor-mediated endocytosis; IEA:Ensembl. DR GO; GO:1900221; P:regulation of beta-amyloid clearance; IEA:Ensembl. DR GO; GO:0032489; P:regulation of Cdc42 protein signal transduction; IEA:Ensembl. DR GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl. DR GO; GO:1902947; P:regulation of tau-protein kinase activity; IEA:Ensembl. DR GO; GO:0002021; P:response to dietary excess; IEA:Ensembl. DR GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl. DR GO; GO:0043691; P:reverse cholesterol transport; IEA:Ensembl. DR GO; GO:0006641; P:triglyceride metabolic process; IEA:Ensembl. DR GO; GO:0042311; P:vasodilation; IEA:Ensembl. DR GO; GO:0034447; P:very-low-density lipoprotein particle clearance; IEA:Ensembl. DR GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; IEA:Ensembl. DR InterPro; IPR000074; ApoA_E. DR Pfam; PF01442; Apolipoprotein; 1. PE 4: Predicted; KW Lipid transport {ECO:0000256|SAAS:SAAS00143435}; KW Lipoprotein {ECO:0000313|EMBL:ADB55604.1}; KW Secreted {ECO:0000256|SAAS:SAAS00143438}; KW Transport {ECO:0000256|SAAS:SAAS00143436}. FT NON_TER 1 1 {ECO:0000313|EMBL:ADB55604.1}. FT NON_TER 170 170 {ECO:0000313|EMBL:ADB55604.1}. SQ SEQUENCE 170 AA; 19868 MW; DB0AA1CCEEB5BFA5 CRC64; ELQAAQARLR SDMEDVRNRL TQYRGELQAM LGQSSEELRA RFASHMRKLR KRVLRDAEDL QRRLAVYKAG VREGAERSVS SIRERLWPLL EQARERNAKV GALATQPLLE RADALGQQLR GQLEEMSSRA RGHLEEMREQ IQEVRVKMEE QADQIRQKAE AFQARLKSWF //